BALAXI PHARMACEUTICALS LIMITED — Board Meeting, 11-11-2025: Outcome of Board Meeting

Balaxi Pharma's board approved Q2 & H1 FY26 consolidated results: Q2 Revenue Rs 56.18 Cr, PAT Rs 0.21 Cr. H1 Revenue Rs 126.92 Cr, PAT Rs 0.50 Cr. They also approved up to USD 4 million equity into its Dubai subsidiary for expansion. Progress on the Hyderabad plant was noted, with setup complete and test manufacturing initiated.